Thomas H. Kean
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Kean sold $15,001-$50,000 in $JNJ on 2025-11-20 — 61 days before HR7165, a bill that could increase operational costs for pharmaceutical companies, was introduced.
Rep. Kean bought $1,001-$15,000 in $TXN on 2025-11-26 — 70 days before HR7274, a bill strengthening federal acquisition security, was introduced.
Rep. Kean sold $15,001-$50,000 in $JNJ on 2025-11-20 — 82 days before S3822, a bill aiming to prohibit common ownership between pharmaceutical companies, was introduced.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $TXN | Texas Instruments Incorporated - Common Stock | $1K-$15K | $165.35 | — | — | Nov 26, 2025 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $15K-$50K | $203.07 | $230.69 | +13.6% | Nov 20, 2025 |
| PARTIAL SELL | $SYK | Stryker Corporation Common Stock | $15K-$50K | $370.22 | $338.34 | -8.6% | Nov 20, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
GAP Supply Act
The GAP Supply Act (HR7528) is an early-stage procedural bill with no funding authorization. It extends a regulatory timeline for compounding facilities during drug shortages but has near-zero near-term market impact. Current real market data shows $VTRS at $15.04 within its 52-week range of $8.19–$16.47, with a +11.32% 30-day gain reflecting broader market trends, not this bill.
Break Up Big Medicine Act
The Break Up Big Medicine Act (S.3822) targets the vertical integration of healthcare giants by prohibiting common ownership of PBMs, insurers, and drug wholesalers. In early committee stage with bipartisan sponsorship, the bill poses a structural risk to UnitedHealth Group's business model while potentially easing pricing pressure on pharmaceutical manufacturers like Pfizer.
Skinny Labels, Big Savings Act
HR6485 (Skinny Labels, Big Savings Act) creates a statutory safe harbor protecting generic and biosimilar manufacturers from patent infringement liability when marketing drugs for non-patented indications, directly reversing the GlaxoSmithKline v. Teva precedent. Generic makers TEVA and VTRS are structural winners, with reduced litigation risk supporting their generic launch strategies. Brand-name manufacturers AMGN, PFE, JNJ, and MRK face accelerated competitive erosion on their top-selling drugs. The bill is early-stage (referred to House Judiciary), but companion Senate bill S43 signals bipartisan interest.
AI Grand Challenges Act of 2026
The AI Grand Challenges Act of 2026 is an early-stage authorization-only bill that creates a prize competition program at NSF but appropriates zero funds. With minimal cosponsors, a single committee referral, and no spending mechanism, it has no near-term market impact.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act (S3847) would retroactively tax inverted companies as domestic corporations, directly hitting MDT, PRGO, and ALLE with $40M to $1.2B in annual tax increases. Market prices already discount this risk: all three are near 52-week lows. The bill is early-stage but has a companion in the House, indicating legislative momentum. Investors holding these names face binary tax-expense risk with limited upside until the bill's path clarifies.
Most Favored Patient Act of 2026
HR7837, the Most Favored Patient Act of 2026, is a bearish catalyst for major pharmaceutical companies with high Medicare exposure. The bill proposes linking US Medicare drug prices to the lowest global price, directly threatening the US pricing premium that supports current industry margins. The bill is in early legislative stages but represents a credible structural threat to pharmaceutical pricing power.
Federal Acquisition Security Council Improvement Act of 2026
HR7274 strengthens the Federal Acquisition Security Council's authority to remove Chinese and other foreign-adversary technology from U.S. government supply chains. The bill passed committee 40-1 and awaits House floor action. Domestic semiconductor manufacturers $TXN and $ON are the clearest immediate beneficiaries, with real 30-day gains of +40.1% and +60.7% respectively, reflecting market pricing of supply chain reshoring momentum. Defense primes $LMT, $GD, and $NOC benefit structurally from reduced technology risk and contract stability, despite recent 30-day declines of -15.7%, -0.4%, and -15.7% due to broader market rotation.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877 (Shane DiGiovanna Act) mandates a 2-year nationwide Medicaid demonstration program covering wound care and OTC drugs for epidermolysis bullosa. The bill is in early legislative stages (referred to committee, 5 cosponsors) with no explicit funding authorized. Market impact is minimal — the affected patient population is small (~3,000-5,000 individuals), and near-term passage is uncertain.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026 (HR7493) is a single-sponsor bill in early committee stage with no near-term market impact. However, Medtronic ($MDT) faces direct structural risk from this bill's retroactive provisions. $MDT is already down 8.17% over 30 days and trading at $79.57, near its 52-week low of $78.91, reflecting broader sector weakness amplified by this legislative overhang.
To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes.
HR7165 (WATCH Act) imposes quarterly inspection mandates on foreign labs conducting NIH-funded animal research, targeting CROs like IQVIA and CRL. Both stocks have declined sharply in the last week, with IQVI down 2.49% and CRL down 3.4% over 7 days, reflecting sector weakness amplified by this regulatory overhang. The bill is early-stage and authorized no new funding, but its compliance costs would pressure margins if enacted.
Other Filings by Thomas H. Kean
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.